Last reviewed · How we verify
Saw Palmetto - weeks 48 - 72
Saw palmetto may inhibit the conversion of testosterone to dihydrotestosterone (DHT), a hormone involved in hair loss and prostate issues.
Saw palmetto may inhibit the conversion of testosterone to dihydrotestosterone (DHT), a hormone involved in hair loss and prostate issues. Used for Benign prostatic hyperplasia (BPH), Androgenetic alopecia.
At a glance
| Generic name | Saw Palmetto - weeks 48 - 72 |
|---|---|
| Sponsor | University of Alabama at Birmingham |
| Drug class | Phytotherapeutic |
| Modality | Small molecule |
| Therapeutic area | Urology |
| Phase | Phase 3 |
Mechanism of action
The exact mechanism of saw palmetto is not fully understood, but it is thought to affect the activity of enzymes involved in the conversion of testosterone to DHT. This may lead to a decrease in DHT levels, which could help alleviate symptoms of benign prostatic hyperplasia (BPH) and androgenetic alopecia.
Approved indications
- Benign prostatic hyperplasia (BPH)
- Androgenetic alopecia
Common side effects
- Gastrointestinal upset
- Allergic reactions
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Saw Palmetto - weeks 48 - 72 CI brief — competitive landscape report
- Saw Palmetto - weeks 48 - 72 updates RSS · CI watch RSS
- University of Alabama at Birmingham portfolio CI